Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303
3SBioADC / XDC

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

CBC Group's R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion
Mirxes

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

JW Therapeutics' Carteyva Granted Breakthrough Therapy Designation by CDE
Breakthrough therapyCAR-T

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

CSPC Pharmaceutical's ADC Pipeline Advances with SYS 6041 Approval
ADC / XDCCancer

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Show More